Pfizer and BioNTech said Thursday that an early trial of a combined Covid-19 and influenza vaccine had produced positive data. The companies are set for a race with Moderna to release their combination vaccines.
Pfizer and German partner BioNTech said the shot performed well in tests which compared it with two stand-alone vaccines. They expect to start a Phase 3 trial within the coming months. “This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for providers, patients, and healthcare systems all over the world,” said Annaliesa Anderson, head of Vaccine Research and Development at Pfizer.
Pfizer shares were down 0.2% in premarket trading on Thursday. American depositary receipts of BioNTech were up 0.3%. The companies will be racing against Moderna , which said earlier this month that its own combination vaccine could be ready to launch as soon as 2025.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC - 🏆 471. / 51 Read more »